Shamburg News · 8-K filed Nov 10, 2026, 4:55 PM EST
Acrivon Therapeutics Hosts EoE Key Opinion Leader Event on New I&I Programs
ACRV · Acrivon Therapeutics, Inc.
- Other event
- Reg FD disclosure
- Materiality: low
On November 10, 2026, Acrivon Therapeutics, Inc. hosted a webcast corporate R&D event with eosinophilic esophagitis key opinion leaders to discuss its new immunology and inflammation programs identified using its AP3 platform. The presentation introduced the ACR-525 JAK1 inhibitor and PKCθ inhibitor preclinical programs and initial development plans in EoE. The presentation is furnished as Exhibit 99.1 under Regulation FD and is not deemed filed.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001193125-26-455669.
Written from the filing by Shamburg Markets. Figures are as reported by the company.